Bioniche Presents Additional Data on the Anticancer Activity of MCC Against Peritoneal Carcinomatosis



    BELLEVILLE, ON, April 16 /CNW/ - Bioniche Life Sciences Inc. (TSX:BNC), a
research-based technology driven Canadian Biopharmaceutical company, presented
data yesterday showing that intraperitoneal administration of the Company's
proprietary Mycobacterial Cell Wall-DNA Complex (MCC) results in significant
anticancer activity against both micrometastases and macrometastases present
in the peritoneal cavity of rats with colon cancer peritoneal carcinomatosis.
The data was presented at the American Association for Cancer Research (AACR)
Annual Meeting 2007, being held from April 14-18 in Los Angeles, California,
USA.
    The study was co-authored by Mario C. Filion, Benoit Filion and Nigel C.
Phillips of Bioniche Life Sciences Inc., Montréal, Québec, Canada and by
Caroline Mignard, Olivier Raguin and Francis Bichat of Oncodesign
Biotechnology, Dijon, France. The study evaluated the in vivo anticancer
activity of MCC against microscopic and macroscopic peritoneal nodes after
administration of rat PROb colon cancer cells in animals.
    "MCC suspension demonstrates significant dose-related anticancer activity
in rats having experimental colon microscopic (micrometastases) and
macroscopic (macrometastases) nodes in the peritoneum," said Nigel C.
Phillips, Senior Vice-President of Scientific Affairs and Chief Scientific
Officer at Bioniche Life Sciences Inc. "These additional data confirm the
potential application of MCC for treatment of patients with peritoneal
metastasis from colorectal cancer."
    "This is of particular interest given that treatment options for
managements of metastases presented in the peritoneal cavity (peritoneal
carcinomatosis) are currently very limited," added Dr. Phillips.
    "Bioniche is currently conducting its Phase III clinical program using
MCC (trademarked Urocidin) for the treatment of non muscle-invasive bladder
cancer," added Graeme McRae, President & CEO of Bioniche Life Sciences Inc.
"The first of two Phase III clinical trials began last November in a patient
population that is refractory (unresponsive) to the current standard therapy,
an area of unmet need. The Company is anxious to proceed with a Phase I/II
clinical trial in intraperitoneal uses of MCC, specifically in the treatment
of ovarian and colorectal cancers, for which there are limited treatment
options available."

    About the Mycobacterial Cell Wall Technology Platform

    Bioniche's core mycobacterial cell wall technology platform comprises a
number of different compositions with a spectrum of activity that comprises
antiviral, antibacterial, immune stimulatory and immune adjuvant, as well as
anticancer and chemotherapeutic activity against cancer cells. A number of
compositions are commercialized for use in veterinary applications, and the
Company is actively developing compositions for use in a number of human
applications.

    About Bioniche Life Sciences Inc.

    Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery, development,
manufacturing, and marketing of proprietary products for human and animal
health markets worldwide. The fully-integrated company employs approximately
185 skilled personnel and has three operating business units: Human Health,
Animal Health, and Food Safety. The Company's primary goal is to develop
proprietary cancer therapies supported by revenues from marketed products in
human and animal health. For more information, please visit www.Bioniche.com.

    Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process, and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.

    %SEDAR: 00013159EF




For further information:

For further information: Jennifer Shea, Corporate Communications &
Investor Relations Manager, Bioniche Life Sciences Inc., Telephone: (613)
966-8058 ext. 1250, Cell: (613) 391-2097, Jennifer.Shea@Bioniche.com

Organization Profile

Telesta Therapeutics Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890